Read on Twitter
With @pfizer and @BioNTech_Group submitting their latest COVID-19 vaccine results, let's dive into what it means!
The vaccine is currently in phase 3, which tests for safety and efficacy in large groups.
43,538 participants are enrolled, with 42% from diverse backgrounds.
43,538 participants are enrolled, with 42% from diverse backgrounds.
This is an interim analysis, and complete data will be released at 164 cases.
This is an mRNA vaccine that will be delivered in two doses.
There was a 90% reduction of disease incidence for patients who received the vaccine compared to those who received a placebo.
Pfizer will seek an Emergency Use Authorization from @US_FDA by the third week of November. Participants will be monitored for two years after the trial.
